reports
HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS ...
HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS FOR THE THREE AND SIX MONTHS ENDED DECEMBER 31, 2025 Shreveport, Louisiana, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Home Federal Bancorp, Inc. of Louisiana (the “Company”) (Nasdaq: HFBL), the holding company of Home Federal Bank, reported net income for the three months ended December 31, 2025, of $1.675 million compared to net income of $1.020 million reported for the three months ended December 31, 2024. The Company’s basic and diluted earnings per share were $0.55 and $0.54, respectively, for the three months ended Decembe...
Cardiff Oncology Announces Positive Update from its Randomized Phase 2...
Cardiff Oncology Announces Positive Update from its Randomized Phase 2 Trial of Onvansertib in First-line RAS-mutated mCRC - Onvansertib added to FOLFIRI/bev first-line standard of care regimen showed dose-dependent improvement in overall response rates and durability trends as measured by progression-free survival in patients with RAS-mutated mCRC – - Data support selection of 30 mg onvansertib dose for registrational program in first-line RAS-mutated mCRC – - Data validate previously reported positive results from Phase 2 trial of onvansertib with FOLFIRI/bev in second-line mCRC bev-naï...
Cardiff Oncology Announces Executive Leadership Changes as it Transiti...
Cardiff Oncology Announces Executive Leadership Changes as it Transitions to Late-Stage Clinical Development SAN DIEGO, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced a leadership transition designed to support the Company’s next phase of growth and advancement toward late-stage development and key clinical and corporate milestones. Mani Mohindru, PhD, a member of Cardiff Oncology’s Board of Directors since 2021 and a seasoned b...
Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Divide...
Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend SHREVEPORT, La., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Home Federal Bancorp, Inc. of Louisiana (the “Company”) (NASDAQ: HFBL), the holding company for Home Federal Bank, announced today that its Board of Directors at their meeting on January 21, 2026, declared a quarterly cash dividend of $0.135 per share on the Company’s common stock. The dividend is payable on February 16, 2026, to the shareholders of record at the close of business on February 2, 2026. Home Federal Bancorp, Inc. of Louisiana is the holding company f...
Adverum Biotechnologies Inc: 2 directors
Two Directors at Adverum Biotechnologies Inc bought 178,699 shares at between 4.220USD and 4.304USD. The significance rating of the trade was 99/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direct...
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored T...
Cardiff Oncology Announces Clinical Data from Investigator-Sponsored Trial with Onvansertib in Chronic Myelomonocytic Leukemia at ASH 2025 SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that clinical data from an investigator-sponsored trial with onvansertib in chronic myelomonocytic leukemia (CMML) will be presented in a poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting. In this Phas...
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conf...
Cardiff Oncology to Present at Sidoti’s Year-End Virtual Investor Conference SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and host one-on-one meetings at Sidoti’s Year-End Virtual Investor Conference, which is taking place from December 10-11, 2025. Details of the presentation can be found below. Presenter: Mark Erlander, PhD (CEO) Date: 12/11/2025Time: 4:00 PM ET Interested pa...
Adverum Reminds Stockholders to Tender their Shares into the Offer by ...
Adverum Reminds Stockholders to Tender their Shares into the Offer by Lilly Mails Letter to Stockholders Highlighting the Certainty of Value the Transaction Delivers to Stockholders Compared to a Liquidation REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of intravitreal gene therapy as a potential One And DoneTM treatment to preserve sight for life, today announced that it has mailed a letter to its stockholders in connection with its pending transaction to be acquired by Eli Lilly and Com...
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcar...
Cardiff Oncology to Present at the Piper Sandler 37th Annual Healthcare Conference SAN DIEGO, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Piper Sandler 37th Annual Healthcare Conference, which is taking place from December 2-4, 2025. Details of the presentation can be found below. Presenters: Mark Erlander, PhD (CEO) Date: 12/02/2025...
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Busin...
Cardiff Oncology Reports Third Quarter 2025 Results and Provides Business Update – Announced positive data from the ongoing Phase 2 CRDF-004 trial evaluating onvansertib + standard of care for the treatment of first-line RAS-mutated metastatic colorectal cancer – – Expects to report an update from the Phase 2 CRDF-004 trial in Q1 2026 – – Cash and investments of $60.6 million as of September 30, 2025, projected runway into Q1 2027 – SAN DIEGO, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to de...
Advantage Solutions Reports Third Quarter 2025 Results
Advantage Solutions Reports Third Quarter 2025 Results Strong Revenues and Adjusted EBITDA growth in Experiential Services partially offsetting softness in Branded Services Generated $98 million in adjusted unlevered free cash flow and ended the quarter with strong cash position of $201 million Rapidly responded to robust demand in high-volume labor businesses generating strong incremental margin Reaffirm Revenue and modestly lower Adjusted EBITDA outlook due to impact of divestiture and macro environment ST. LOUIS, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. ...
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
Cardiff Oncology to Participate in Two Upcoming Investor Conferences SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in two upcoming investor conferences in November 2025. Guggenheim Securities 2nd Annual Healthcare Innovation ConferenceFormat: Fireside Chat and 1x1 MeetingsPresenters: Mark Erlander, PhD (CEO) Date: 11/11/2025Time: 9:30 AM ET Stifel 2025 Healthcare ConferenceFo...
- Jacob Mekhael
Merus Petosemtamab phase 2 mCRC results show high response rates
Merus announced interim clinical data (29 July 2025 cutoff) from the ongoing phase 2 trial of petosemtamab (EGFR x LGR5 bispecific antibody) + standard of care FOLFOX/FOLFIRI (chemo) in 1L, 2L metastatic CRC (mCRC) and petosemtamab monotherapy in 3L+ mCRC. The results were presented at the AACR-NCI-EORTC, and confirm and build upon the responses reported from an initial dataset with a previous cut-off date (28 April 2025). We view the numbers as competitive vs. cetuximab (EGFR antibody) + FOLFOX...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer De...
Merus’ Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety – 100% response rate in 1L left-sided mCRC (n=8, confirmed and unconfirmed) – 62% response rate in 2L left- and right-sided mCRC (n=13, confirmed and unconfirmed) UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates ...
Advantage Solutions Announces Date for its Third Quarter 2025 Financia...
Advantage Solutions Announces Date for its Third Quarter 2025 Financial Results and Conference Call ST. LOUIS, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ GS: ADV), announced today that it will release financial results for the third quarter at 7 a.m. EDT on Nov. 6, 2025, followed by a conference call at 8:30 a.m. EDT on the same day. The conference call can be accessed live by dialing 1-800-715-9871 for U.S. callers or 1-646-307-1963 for international callers. The conference ID is 5720569. Approximately three hours after the call, a replay will be available by dia...
HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS ...
HOME FEDERAL BANCORP, INC. OF LOUISIANA REPORTS RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2025 Shreveport, La, Oct. 23, 2025 (GLOBE NEWSWIRE) -- Home Federal Bancorp, Inc. of Louisiana (the “Company”) (Nasdaq: HFBL), the holding company of Home Federal Bank, reported net income for the three months ended September 30, 2025, of $1.599 million compared to net income of $941,000 reported for the three months ended September 30, 2024. The Company’s basic and diluted earnings per share were $0.53 and $0.52, respectively, for the three months ended September 30, 2025 compar...
Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Divide...
Home Federal Bancorp, Inc. of Louisiana Declares Quarterly Cash Dividend and Announces Approval of Stock Repurchase Program SHREVEPORT, La., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Home Federal Bancorp, Inc. of Louisiana (the “Company”) (NASDAQ: HFBL), the holding company for Home Federal Bank, announced today that its Board of Directors at their meeting on October 15, 2025, declared a quarterly cash dividend of $0.135 per share on the Company’s common stock. The dividend is payable on November 10, 2025, to the shareholders of record at the close of business on October 27, 2025. The Company al...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
Merus Announces Publication of an Abstract on Petosemtamab in Metastat...
Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Petosemtamab in combination with FOLFOX /FOLFIRI (1L and 2L mCRC) and as monotherapy (3L+ mCRC), demonstrates antitumor activity and a manageable safety profile UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Bicloni...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.